Skip to main content

Blog Exposure - Boston Scientific’s Spectra WaveWriter(TM) Spinal Cord Stimulator System Gets FDA Approval

LONDON, UK / ACCESSWIRE / January 16, 2018 / Active-Investors.com has just released a free research report on Boston Scientific Corp. (NYSE: BSX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BSX as the Company's latest news hit the wire. On January 11, 2018, the Company, a worldwide developer, manufacturer and marketer of medical devices, declared that the US Food and Drug Administration (FDA) has approved its Spectra WaveWriter™ Spinal Cord Stimulator (SCS) System. This is the first and only system approved by the FDA to simultaneously provide paresthesia-based and sub-perception therapy. This unique system enables physicians and patients to combine therapeutic options, customize therapy, and share real-time feedback. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Boston Scientific most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=BSX

Chronic Pain Affects Millions

Chronic Pain is the biggest cause of disability in adults in the US and it affects over 100 million Americans. Although the prescriptions for opioids in America have quadrupled since 1999, there has been no change in the amount of pain reported in the US.

Need for Personalized Pain Relief Therapy

People suffering with chronic pain experience pain differently and pain also evolves over time. Many a time, patients become less responsive as their body becomes accustomed to treatment. This highlights the need for personalized pain relief therapy.

However, at present, the medical community has limited options to offer personalized pain relief therapy.

Spectra Wavewriter SCS System, a Non-Opioid Treatment Option with Personalized Therapy

SCS is a non-opioid alternative for treating chronic pain. Maulik Nanavaty, the President and Senior Vice President at Neuromodulation - Boston Scientific stated that his team is introducing the industry-leading SCS technology to provide patients with permanent relief from chronic pain. The Company intends to further invest in research and enhance treatment options for chronic pain by discovering new innovative non-opioid solutions.

The SCS system works by sending low electrical pulses to the spinal cord to interrupt pain signals. These electrical pulses vary in frequency, pulse width, and amplitude. While the paresthesia-based therapy provides pain relief with a light tingling sensation, sub-perception therapy functions without that sensation. Thus, patients get the option to combine both therapies to target one specific area of pain or use each therapy as required for managing multiple areas of pain. Moreover, patients can also share real-time feedback through the system's remote control. These features help address the unique pain relief needs of each patient.

Spectra Wavewriter SCS System, Result of Multiple Research Studies

The Spectra WaveWriter™ System is the result of a decade of clinical research on enhancing sub-perception and delivering multiple therapies for more effective, long-term pain relief.

Clinical studies such as the PROCO study and the WHISPER study provided meaningful information for the development of this system.

The PROCO study was a multi-center, prospective, double blind, randomized study wherein patients acted as their own control. The study proved that when proper target and dose are identified in de novo patients, similar pain relief and improvement in quality of life measures are achieved, independent of the type of frequency (from 1 kHz up to 10 kHz) used in sub-perception SCS therapy.

The WHISPER study was a multi-center, prospective, cross over, randomized, and controlled study, designed to assess the long-term safety and effectiveness of sub-perception SCS pain relief therapy.

Stock Performance Snapshot

January 12, 2018 - At Friday's closing bell, Boston Scientific's stock was slightly up 0.11%, ending the trading session at $27.46.

Volume traded for the day: 8.68 million shares.

Stock performance in the last month – up 7.22%; past twelve-month period – up 16.75%; and year-to-date - up 10.77%

After last Friday's close, Boston Scientific's market cap was at $37.68 billion.

Price to Earnings (P/E) ratio was at 45.31.

The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry. This sector was up 0.7% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visithttp://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.